arimoclomol
Treatment for Niemann-Pick Disease, type C
Orphazyme Announces FDA Acceptance and Priority Review of New Drug Application for Arimoclomol for Niemann-Pick Disease Type C
Copenhagen, Denmark, September 16, 2020 – Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company’s New Drug Application (NDA) for arimoclomol for the treatment of NPC.
The FDA grants Priority Review to applications for potential therapies that, if approved, could offer a significant improvement in safety or effectiveness, diagnosis, or prevention of serious conditions. This designation shortens the review period from the standard 10 months to six months from the acceptance of the NDA. The FDA has set a target action date of March 17, 2021 under the Prescription Drug User Fee Act (PDUFA) and has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application.
Kim Stratton, Chief Executive Officer, Orphazyme, said, “The filing acceptance marks a significant milestone in our journey towards our first potential approval of arimoclomol for NPC, a devastating and often fatal disease for which there is no approved therapy in the U.S. We look forward to collaborating with the FDA as they complete their review of this NDA to address the unmet medical need in NPC, and meanwhile are working to expand our U.S. activities in preparation for potential commercial availability next year.”
“Acceptance of the arimoclomol filing by the FDA is another major step forward in the effort to bring a treatment to people affected by Niemann-Pick disease Type C and is a reflection of the commitment of the entire community coming together to support promising research,” said Joslyn Crowe, Executive Director of the National Niemann-Pick Disease Foundation.
Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for arimoclomol in NPC in H2 2020.
Source: Orphazyme A/S
Posted: September 2020
Related Articles
More News Resources
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Related Post
Mar
10 Yoga Poses to Boost the Immune System
As the days get more limited and temperatures decrease, we might have seen our schedules are advising us that the Christmas season is quick drawing nearer. That additionally implies that cold and influenza season is back! Yet again sadly for.
Read MoreMar
7 Health Benefits of Attending Concerts
Music resembles an embrace for your spirit. Music is quite possibly of the best gift we have on this planet. It assists us with communicating our feelings, it interfaces with others, and it could actually help us unwind and ease.
Read MoreMar
Why Are Cancer Rates Rising in Adults Under 50?
One of the most widely recognized risk factors for disease is something we can't hope to make any significant difference with age. Our disease risk increments as we age, with the typical age at conclusion drifting around 68. Yet, another concentrate.
Read MoreFeb
World Mental Health Day 2023
World Emotional wellness Day 2023 is a chance for individuals and networks to join behind the subject 'Psychological well-being is a general basic freedom" to further develop information, bring issues to light and drive activities that advance and safeguard everybody's.
Read More